Synvista Therapeutics Announces Initiation of the BREAK Study of Alagebrium for Diastolic Hea...(ities for heart failure. We look forward...)
| HOME >> BIOLOGY >> TECHNOLOGY |
ities for heart failure. We look forward to seeing the results of the BREAK study before the end of next year."
About Alagebrium
Alagebrium is Synvista's clinical candidate for interfering with A.G.E.- related sclerosis and fibrosis of the heart, kidney and other tissues leading to heart failure, diabetic nephropathy and other disorders. It is a proprietary A.G.E. crosslink breaker that functions unlike any previously developed pharmaceutical agents to reverse the disease states associated with age or diabetes-related stiffening of vessels, tissues and organs. Alagebrium has completed a series of single- and multiple-dose Phase 1 studies in humans and has demonstrated efficacy in heart failure in several open-label Phase 2 trials. To date approximately 1,000 patients have received alagebrium treatment and the drug continues to exhibit a clean safety profile.
About Heart Failure
Heart failure is a complex clinical syndrome that can result from any structural or functional cardiac disorder that impairs the ability of the ventricle to fill with or eject blood. The primary manifestations of heart failure are dyspnea and fatigue, which may limit exercise tolerance, result in fluid retention, and lead to pulmonary congestion and peripheral edema. These abnormalities impair the functional capacity and quality of life of affected individuals.
Heart failure is a major and growing global public health problem. Approximately 5 million patients in the U.S. and about 10 million in Europe have heart failure, according to the American Heart Association. The number of heart failure deaths has increased steadily despite advances in treatment. Heart failure results in more than 1 million hospitalizations at a cost of more than $15 billion annually in the U.S. alone.
Most of the available treatments for heart failure are not aimed at the
underlying pathophysiological processes that occur in the heart and blood
vessels. In this respect, the Com
'/>"/>
| SOURCE Synvista Therapeutics, Inc. Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. Synvista Therapeutics to Present at Acumen BioFin Rodman & Renshaw 5th Annual Global Healthcare Conference
2. Synvista Therapeutics Increases Commercial Focus by Appointing David C. Tantillo Senior Director of Marketing and Sales
3. Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes
4. Synvista Therapeutics to Present at the 10th Annual BIO CEO & Investor Conference
5. Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis
6. Synvista Therapeutics to be Featured on Wallst.net
7. Synvista Therapeutics to Present at the BIO InvestorForum 2007
8. TorreyPines Therapeutics to Host First Quarter 2008 Results Conference Call and Webcast
9. President and CEO of Velcura Therapeutics Inc. Named the 2008 Grant Thornton Leader and Innovator of the Year
10. NuVasive Signs Definitive Agreement to Acquire Osteocel Biologics Business from Osiris Therapeutics
11. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |